Telavancin is a topic covered in the
Washington Manual of Medical Therapeutics.
To view the entire topic, please sign in or purchase a subscription.
The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:
-- The first section of this topic is shown below --
General Principles
Telavancin (7.5–10 mg/kg q24–48h, based on CrCl) is a lipoglycopeptide antibiotic that is FDA approved for treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by S. aureus and for complicated skin and skin structure infections. Telavancin is broadly active against gram-positive bacteria, including MRSA, VISA, heteroresistant VISA (hVISA), daptomycin- and linezolid-resistant S. aureus, streptococci, vancomycin-sensitive enterococci, and some gram-positive anaerobes. The agent is not active against gram-negative bacteria, vancomycin-resistant S. aureus, and VRE.
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Citation
Williams, Dominique, et al., editors. "Telavancin." Washington Manual of Medical Therapeutics, 35th ed., Wolters Kluwer Health, 2016. Washington Manual, www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602248/all/Telavancin.
Telavancin. In: Williams D, Ramgopal R, Gdowski M, et al, eds. Washington Manual of Medical Therapeutics. 35th ed. Wolters Kluwer Health; 2016. https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602248/all/Telavancin. Accessed October 18, 2019.
Telavancin. (2016). In Williams, D., Ramgopal, R., Gdowski, M., Dretler, A., & Bhat, P. (Eds.), Washington Manual of Medical Therapeutics. Available from https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602248/all/Telavancin
Telavancin [Internet]. In: Williams D, Ramgopal R, Gdowski M, Dretler A, Bhat P, editors. Washington Manual of Medical Therapeutics. Wolters Kluwer Health; 2016. [cited 2019 October 18]. Available from: https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602248/all/Telavancin.
TY - ELEC
T1 - Telavancin
ID - 602248
ED - Williams,Dominique,
ED - Ramgopal,Rajeev,
ED - Gdowski,Mark,
ED - Dretler,Alexandra,
ED - Bhat,Pavat,
BT - Washington Manual of Medical Therapeutics
UR - https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602248/all/Telavancin
PB - Wolters Kluwer Health
ET - 35
DB - Washington Manual
DP - Unbound Medicine
ER -
Washington Manual of Medical Therapeutics
